Brain natriuretic peptide and optimal management of heart failure

Aside from the important role of brain natriuretic peptide (BNP) in diagnosis, and differential diagnosis of heart failure, this biological peptide has proved to be an independent surrogate marker of rehospitalization and death of the fatal disease. Several randomized clinical trials demonstrated that drugs such as beta blocker, angiotensin converting enzyme inhibitor, spironolactone and amiodarone have beneficial effects in decreasing circulating BNP level during the management of chronic heart failure. The optimization of clinical decision-making appeals for a representative surrogate marker for heart failure prognosis. The serial point-of-care assessments of BNP concentration provide a therapeutic goal of clinical multi-therapy and an objective guidance for optimal treatment of heart failure. Nevertheless new questions and problems in this area remain to be clarified. On the basis of current research advances, this article gives an overview of BNP peptide and its property and role in the management of heart failure.

[1]  Y. Pinto,et al.  High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. , 1998, Journal of the American College of Cardiology.

[2]  A. D. de Bold,et al.  Atrial natriuretic factor: a hormone produced by the heart. , 1985, Science.

[3]  H Sumida,et al.  Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. , 1996, American heart journal.

[4]  M. Ohyanagi,et al.  Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty , 2000, Clinical cardiology.

[5]  J. Sanderson,et al.  Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. , 1995, British heart journal.

[6]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[7]  D. Goeddel,et al.  Molecular Biology of the Natriuretic Peptides and Their Receptors , 1992, Circulation.

[8]  Naoto Minamino,et al.  A new natriuretic peptide in porcine brain , 1988, Nature.

[9]  N. Minamino,et al.  C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. , 1990, Biochemical and biophysical research communications.

[10]  D. Fukai,et al.  Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. , 1997, American heart journal.

[11]  M. Shoda,et al.  Amiodarone Decreases Plasma Brain Natriuretic Peptide Level in Patients with Heart Failure and Ventricular Tachyarrhythmia , 2003, Cardiovascular Drugs and Therapy.

[12]  A. Richards,et al.  Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. , 1996, The American journal of physiology.

[13]  N. Minamino,et al.  Cloning and sequence analysis of cDNA encoding a precursor for porcine brain natriuretic peptide , 1988 .

[14]  M. Esler,et al.  Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. , 2001, Journal of the American College of Cardiology.

[15]  A. Richards,et al.  Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. , 1997, The American journal of physiology.

[16]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[17]  D. Kremastinos,et al.  Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty , 2000, Clinical cardiology.

[18]  N. Minamino,et al.  Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. , 1991, Biochemical and biophysical research communications.

[19]  B. Kisch.  Electron microscopy of the atrium of the heart. I. Guinea pig. , 1956, Experimental medicine and surgery.

[20]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[21]  G. Fonarow.  B-Type Natriuretic Peptide: Spectrum of Application. Nesiritide (Recombinant BNP) for Heart Failure , 2003, Heart Failure Reviews.

[22]  T. MacDonald,et al.  Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects. , 1995, Clinical science.

[23]  I. Zineh,et al.  The Evolving Role of Nesiritide in Advanced or Decompensated Heart Failure , 2003, Pharmacotherapy.

[24]  H. Itoh,et al.  Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.

[25]  D. Murdoch,et al.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.

[26]  K. Jensen,et al.  Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. , 1998, The American journal of physiology.

[27]  C. Frampton,et al.  Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension , 1993, Journal of hypertension.

[28]  G. Habib,et al.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. , 2002, Circulation.

[29]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.

[30]  D. Gardner,et al.  Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. , 1995, Hypertension.

[31]  菊田 浩一.  Increased plasma levels of B-type natriuretic peptide in patients with unstable angina , 1998 .

[32]  J. Henry,et al.  The possible role of cardiac atrial stretch receptors in the induction of changes in urine flow , 1956, The Journal of physiology.

[33]  M. D. de Bold,et al.  The physiological and pathophysiological modulation of the endocrine function of the heart. , 2001, Canadian journal of physiology and pharmacology.

[34]  B. Bruneau,et al.  Mechanical and neuroendocrine regulation of the endocrine heart. , 1996, Cardiovascular research.

[35]  A. Richards,et al.  Bioactivity and interactions of adrenomedullin and brain natriuretic peptide in patients with heart failure. , 1999, Hypertension.

[36]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[37]  K. Hosoda,et al.  Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. , 1992, Endocrinology.

[38]  T. MacDonald,et al.  Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. , 1996, Circulation.

[39]  Meihong Lin,et al.  Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. , 1995, The Journal of clinical investigation.

[40]  Michihisa Jougasaki,et al.  Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.

[41]  A. Kroon,et al.  Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. , 1999, Cardiovascular research.

[42]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[43]  A. Maisel.  Nesiritide: a new therapy for the treatment of heart failure. , 2003, Cardiovascular toxicology.

[44]  C. Frampton,et al.  Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. , 1995, The American journal of physiology.

[45]  R. Berger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.